Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANT3310 and Meropenem lung penetration in healthy volunteers
NCT06916156Phase 1Completed
- Sponsor
- Antabio
- Start
- Apr 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pilabactam, sponsored by Antabio. Primary endpoints: Maximum Plasma Concentrations of ANT3310 and Meropenem, Area Under the Concentration-Time Curve from 0 to 8 Hours Post-Dose and 8 more. Started Apr 2025; status: completed.
02
Drugs
pilabactam
Beyond the preview
Go deeper on NCT06916156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916156.